Sensipar

Sensipar - Cinacalcet (INN) is a drug that acts as a calcimimetic (i.e. it mimics the action of calcium on tissues) by allosteric activation of the calcium-sensing receptor that is expressed in various human organ tissues. It is sold by Amgen under the trade name Sensipar® in North America and Australia and as Mimpara® in Europe. Cinacalcet is used to treat hyperparathyroidism (elevated parathyroid hormone levels), a consequence of parathyroid tumors and chronic renal failure.

For dialysis patients . . .

Sensipar® is a medicine that can help treat dialysis patients with imbalances of phosphorus, calcium, and PTH, known as secondary hyperparathyroidism. On this site, you will learn about secondary HPT in dialysis patients and treatment with Sensipar®.

The condition you may know the least about can have a big impact on your health.

This condition is called secondary hyperparathyroidism (high-per-pair-uh-THIGH-royd-izm), or secondary HPT. In secondary HPT, your parathyroid glands make too much parathyroid hormone (PTH), your kidneys do not produce enough vitamin D, and your calcium and phosphorus are out of balance. Even though you may not have any symptoms, treating secondary HPT is important. Remember to Always Seek Advice from your Physician.